Adipose Or Epithelium Patents (Class 424/574)
-
Patent number: 12091408Abstract: The present invention provides compounds having store overload-induced Ca2+ release (SOICR) inhibitory activity and methods for producing and using the same. In particular, compounds of the invention is of the formula: R1—X1-L-X2—R2, wherein R1, X1, L, X2, and R2 are those defined herein.Type: GrantFiled: September 27, 2014Date of Patent: September 17, 2024Assignee: UTI Limited PartnershipInventors: Tom Back, Wayne Chen, Chris Smith, Dawei Jiang
-
Patent number: 11406685Abstract: Disclosed herein are methods and compositions for providing mixtures of FGF2 isoforms that are biologically active. The biological activities include, but are not limited to, stimulation of proliferation of neural precursor cells, stimulation of proliferation of endothelial cells, stimulation of development of neural precursor cells, and stimulation of development of astrocytes.Type: GrantFiled: June 12, 2019Date of Patent: August 9, 2022Assignee: SanBio, Inc.Inventors: Irina Aizman, Damien Bates
-
Patent number: 11191788Abstract: An acellular soft tissue-derived matrix suitable for use as a medical graft or implant may comprise, for example, a delipidated, decellularized adipose tissue matrix. The delipidated, decellularized adipose tissue matrix is substantially free of substances that pose a significant risk of causing an immunogenic response in a patient receiving the matrix. Methods for producing the delipidated, decellularized adipose tissue matrix include the steps of delipidating an adipose tissue sample, followed by decellularizing the delipidated adipose tissue sample. The resulting delipidated, decellularized adipose tissue matrix contains a proportion of Type IV collagen which is greater than the proportion of Type IV collagen contained in a matrix produced by decellularizing an adipose tissue sample prior to delipidating.Type: GrantFiled: February 5, 2020Date of Patent: December 7, 2021Assignee: Musculoskeletal Transplant FoundationInventors: Yen-Chen Huang, Asia Ivery, Bryan Choi, Benjamin Schilling, Manh-Dan Ngo
-
Patent number: 11141510Abstract: A bio-ink composition comprises a plurality of bio-block, in which the bio-blocks can serve as basic building blocks in cell-based bioprinting. The bio-blocks, pharmaceutical compositions comprising the bio-blocks, methods of preparing artificial tissues, tissue progenitors, or multi-dimensional constructs, and methods of preparing the bio-blocks are also provided. The bio-blocks, and the multi-dimensional constructs, artificial tissues, and tissue progenitors comprising the bio-blocks or prepared by the methods described herein are useful for tissue engineering, in vitro research, stem cell differentiation, in vivo research, drug screening, drug discovery, tissue regeneration, and regenerative medicine.Type: GrantFiled: March 22, 2019Date of Patent: October 12, 2021Assignee: Revotek Co., Ltd.Inventors: Yujian James Kang, Xiao Zuo
-
Patent number: 11071706Abstract: The present invention relates to a cosmetic or pharmaceutical composition containing a cell culture medium and, as an active ingredient, albumin, hyaluronic acid or collagen. The composition according to the present invention can be useful as a cosmetic or pharmaceutical composition for alleviating, preventing or treating skin wounds, skin diseases or skin conditions, by increasing the recovery capability of cells.Type: GrantFiled: March 31, 2017Date of Patent: July 27, 2021Assignee: BIOCOZ GLOBAL KOREA CORP.Inventors: Chan Wha Kim, Young Joon Kim
-
Patent number: 10894947Abstract: A method of creating a protein rich conditioned medium. The method includes culturing mesenchymal stem cells in a container utilizing a first growth medium, allowing a time period for proliferation of the mesenchymal stem cells until a desired level of confluence is achieved in the container, discarding a supernatant from the container, adding a second medium to the container, incubating the mesenchymal stem cells, and collecting the conditioned medium. The method produces significantly higher quantities of byproducts secreted by the mesenchymal stem cells. Byproducts are usable for wound healing, disease treatment, cosmetic, or other beneficial effects when applied or otherwise delivered to a patient.Type: GrantFiled: March 15, 2017Date of Patent: January 19, 2021Assignee: HOPE BIOSCIENCES, LLCInventor: Hyeonggeun Park
-
Patent number: 10821206Abstract: Method of the osteoreparative processes' correction and/or bone defect restoration by means of human cell-based products (cell and/or tissue transplants) and the method of its manufacturing. The invention a creates and establishes conditions for osteoreparative processes restoration in destroyed bone tissue by osteoreparation cell sources restoration as the result of use cell technologies and bone tissue engineering methods, e.g. scaffold-guided regeneration, particularly by means of cell transplantation by injection and/or transplantation of original three-dimensional osteoreparative prevascularized graft (3D-OPG). Manufacturing of medical products and preparations of the product based on human cells (cell and/or tissue transplants) is dedicated for impaired osteoreparative processes correction and/or bone defect restoration.Type: GrantFiled: November 4, 2016Date of Patent: November 3, 2020Assignee: ILAYA USA CORPORATIONInventors: Volodymyr Mykhaylovych Oksymets, Dmytro Oleksandrovych Zubov, Roman Hennadiyovych Vasyliev
-
Patent number: 10801009Abstract: The present invention relates to: a cosmetic composition for improving the condition of the skin, containing, as active ingredients, a cell culture medium, an epidermal growth factor and a bovine serum albumin; a method for improving the condition of the skin by using the same; and a method for preventing or treating skin diseases. According to the present invention, the cosmetic composition can exhibit excellent wrinkle-reducing and wound-healing effects even when only a small amount of EGF is used, and thus can be useful in improving the condition of the skin or in preventing or treating skin diseases.Type: GrantFiled: November 17, 2015Date of Patent: October 13, 2020Assignee: BIOCOZ GLOBAL KOREA CORP.Inventors: Chan Wha Kim, Young Joon Kim, Hyun Jung Kim
-
Patent number: 10564114Abstract: Alternatives described herein relate to methods for detecting, identifying, and/or diagnosing eating disorders, nutritional deficiencies, and/or malnutrition, including conditions such as bulimia nervosa and/or anorexia nervosa, by using X-ray diffraction on a sample of a tested subject's hair. In some alternatives, once an eating disorder, nutritional deficiency, or malnutrition is detected, identified, or diagnosed using the X-ray diffraction approaches set forth herein, a subject identified as having an eating disorder, nutritional deficiency, or malnutrition is provided counseling for the disorder and/or a medicament to treat, inhibit, or ameliorate said eating disorder or malnutrition, including Prozac, ami trip tyline, fluoxe tine, imipramine, Nardil, Tofranil, desipramine, Sarafem, Norpramin, and/or phenelzine.Type: GrantFiled: June 3, 2015Date of Patent: February 18, 2020Assignee: STRUCTURE-ASE INCORPORATEDInventors: Steven Richard Herron, Kent Hatch, Savannah Marriott, Diane Spangler
-
Patent number: 10426802Abstract: A sheet-shaped cell culture and method for producing a sheet-shaped cell culture are disclosed having a high activity such as high cytokine productivity and a production method thereof. The method for producing a sheet-shaped cell culture can include freezing cells, thawing the frozen cells and forming a sheet-shaped cell culture. A sheet-shaped cell culture which is produced by the production method and which has a high activity and a method for treating a disease associated with an abnormality of a tissue with the sheet-shaped cell culture.Type: GrantFiled: November 17, 2015Date of Patent: October 1, 2019Assignee: TERUMO KABUSHIKI KAISHAInventors: Kenta Sakamoto, Kouichirou Yori
-
Patent number: 10091983Abstract: The present invention relates generally to systems and methods for preparing, storing, shipping and using skin equivalents made by organotypic culture. In particular, the present invention relates to systems and methods for cryopreserving viable skin substitutes.Type: GrantFiled: March 13, 2014Date of Patent: October 9, 2018Assignee: Stratatech CorporationInventors: B. Lynn Allen-Hoffmann, John C. Pirnstill, Kenneth R. Gratz, Allen R. Comer
-
Patent number: 9907745Abstract: The present invention generally relates to cosmetic compositions comprising serum derived from cultured keratinocyte and fibroblast cells. The invention also relates to methods of producing serum for use in the cosmetic compositions through novel cell culture techniques.Type: GrantFiled: January 15, 2015Date of Patent: March 6, 2018Assignee: SERUCELL CORPORATIONInventor: Walter De Paula Neto
-
Patent number: 9446189Abstract: Devices and methods for tissue transfer are described where a cannula may be inserted into the breast of a subject at one of several points of entry. Insertion of the cannula into the breast may be accomplished by using a guidance system to distinguish between tissue types. Once desirably positioned, the cannula may be withdrawn from the breast while automatically (or manually) injecting the fat in multiple deposits of adipose tissue or fat such that the deposited fat remains within the tract formed by the withdrawn cannula. Multiple tracts of the deposited fat may be injected within the breast until the breast has been desirably remodeled and/or augmented.Type: GrantFiled: January 16, 2013Date of Patent: September 20, 2016Assignee: LifeCell CorporationInventors: Joseph Rimsa, Brian J. Domecus, Christopher S. Jones, Paul James Lingane
-
Publication number: 20150147409Abstract: A combination of therapeutic factors derived from non-adherent or poorly adherent stromal vascular fraction (SVF) cells exposed to protein-free basal medium are disclosed.Type: ApplicationFiled: November 21, 2014Publication date: May 28, 2015Inventors: Keith L. March, Brian H. Johnstone
-
Patent number: 9005605Abstract: The specification discloses compositions and methods for treating a soft tissue defect of an individual.Type: GrantFiled: February 16, 2012Date of Patent: April 14, 2015Assignee: Allergan, Inc.Inventors: Dennis E. Van Epps, Guang-Liang Jiang, Wha Bin Im
-
Publication number: 20150064147Abstract: Hydrogels comprising a macromolecular matrix and water may be used to augment soft tissue of a human being, promote or support cell or tissue viability or proliferation, create space in tissue, and for other purposes. A macromolecular matrix may comprise a hyaluronic acid component crosslinked to a collagen component.Type: ApplicationFiled: November 6, 2014Publication date: March 5, 2015Applicant: Allergan, Inc.Inventors: Jacob F. Pollock, Lauren E. Kokai, CUNQI Cui, Xiaojie Yu, Dennis E. Van Epps, Darin J. Messina
-
Publication number: 20150064273Abstract: Mesenchymal stem cell conditioned medium and methods for preparing the conditioned medium are provided. The methods comprise culturing MSCs in a medium comprising nicotinamide or nicotinamide and fibroblast growth factor 4 (FGF4) and collecting the conditioned medium. Compositions comprising the mesenchymal stem cell conditioned medium and uses thereof are also provided.Type: ApplicationFiled: February 13, 2013Publication date: March 5, 2015Inventors: Tony Peled, Yair Steinhardt
-
Patent number: 8962035Abstract: Disclosed are tissue graft compositions made of materials having different densities, methods of making, and methods of treatment for restoring tissues in a patient.Type: GrantFiled: September 19, 2013Date of Patent: February 24, 2015Assignee: ACell, Inc.Inventors: Rodney W. Bosley, Jr., Clay Fette
-
Publication number: 20150037435Abstract: Provided are a culture medium of an adipose-derived stem cell, a method for preparing the same, and a composition for promoting hair growth, in which the composition includes the culture medium. The adipose-derived stem cell (ADSC-T) according to the present invention exhibits long lifespan, improved cell proliferation rate, and extended proliferation period, as compared with a primary adipose-derived stem cell (ADSC), and thus, the adipose-derived stem cell (ADSC-T) can be usefully used for the study about the adipose-derived stem cell and the mass production of the culture medium of the adipose-derived stem cell. In addition, according to the present invention, the culture medium of the adipose-derived stem cell (ADSC-T) that expresses a T antigen of SV40 exhibits excellent hair growth effectiveness and can be usefully used as a raw material for the hair loss prevention and hair growing agents.Type: ApplicationFiled: August 29, 2012Publication date: February 5, 2015Inventors: Dong Wan Kim, Mi Jung Seo, Gwang Lee, Woo Hong Joo, Sun Hee Kim
-
Publication number: 20150037436Abstract: An acellular soft tissue-derived matrix includes a collagenous tissue that has been delipidated and decellularized. Adipose tissue is among the soft tissues suitable for manufacturing an acellular soft tissue-derived matrix. Exogenous tissuegenic cells and other biologically-active factors may be added to the acellular matrix. The acellular matrix may be provided as particles, a slurry, a paste, a gel, or in some other form. The acellular matrix may be provided as a three-dimensional scaffold that has been reconstituted from particles of the three-dimensional tissue. The three-dimensional scaffold may have the shape of an anatomical feature and serve as a template for tissue repair or replacement. A method of making an acellular soft tissue-derived matrix includes steps of removing lipid from the soft tissue by solvent extraction and chemical decellularization of the soft tissue.Type: ApplicationFiled: July 30, 2014Publication date: February 5, 2015Applicant: MUSCULOSKELETAL TRANSPLANT FOUNDATIONInventors: Yen-Chen Huang, Asia Ivery, Bryan Choi, Benjamin Schilling, Manh-Dan Ngo
-
Publication number: 20150017254Abstract: Methods for treating a cardiovascular disorder comprising concomitant administration of one or more extracellular matrix (ECM) based compositions directly to damaged or diseased cardiovascular tissue associated with the cardiovascular disorder, and provision of ventricular assistance. In a preferred embodiment, the ECM based compositions include an ECM material derived from a mammalian source.Type: ApplicationFiled: June 11, 2013Publication date: January 15, 2015Inventors: Robert G. Matheny, Anna Fallon
-
Publication number: 20140255507Abstract: The synthesis of collagen and proteoglycan in chondrocytes, such as intervertebral disc cells, articular chondrocytes and meniscal cells is promoted by administration of an extract from inflamed tissue inoculated with vaccinia virus.Type: ApplicationFiled: October 11, 2011Publication date: September 11, 2014Applicants: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, NIPPON ZOKI PHARMACEUTICAL CO., LTD.Inventors: Koichi Masuda, Mitsuru Naiki
-
Publication number: 20140234272Abstract: The invention relates to compositions comprising (i) adipose tissue-derived cell secretions or (ii) an adipose tissue-derived cell suspension, optionally comprising adipocytes, or (iii) a combination of adipose tissue-derived cell secretions and an adipose tissue-derived cell suspension, optionally comprising adipocytes, and to their use in pharmaceutical compositions and methods for treatment of various conditions. The invention also relates to improved methods, agents and compositions for cryopreservation of cells.Type: ApplicationFiled: September 21, 2012Publication date: August 21, 2014Applicant: Cell Ideas Pty Ltd.Inventors: Graham Vesey, Rebecca Anne Webster, Richard Lilischkis
-
Publication number: 20140170234Abstract: The present specification discloses compositions and methods of transplanting tissue, for example, in breast augmentation procedures. The compositions include adipose tissue and compounds that reduce tissue volume loss and increase survival rate of the adipose tissue when the composition is introduced into breast tissue.Type: ApplicationFiled: February 25, 2014Publication date: June 19, 2014Applicant: Allergan, Inc.Inventors: Dennis E. Van Epps, Guan-Liang Jiang, Wha Bin Im
-
Publication number: 20140170233Abstract: The invention relates to a natural feed mixture for breeding domesticated water birds, comprising a high carbohydrate containing basic component poor in methyl-donors, a component rich in carbohydrates, having hepatic insulin-sensitizing properties, hypothalamic appetite-stimulating plant parts, natural substances blocking cholesterol synthesis in the liver, and an additive for protecting the formation of non-cholesterol- mevalonate products.Type: ApplicationFiled: December 17, 2013Publication date: June 19, 2014Applicant: LIBAFOOD TECH Kft.Inventors: Zoltán SZILVÁSSY, Péter TÓTH, Enikö FÖLDI, Zsolt Tibor LAMPÉ, József MÉSZÁROS, Pál ANTON
-
Patent number: 8753690Abstract: Methods and compositions generating and using an interleukin-1 receptor antagonist (IL-1ra)-rich solution. Methods for generating and isolating interleukin-1 receptor antagonist include incubating adipose tissue and/or adipocytes with polyacrylamide beads to produce interleukin-1 receptor antagonist. The interleukin-1 receptor antagonist is isolated from the polyacrylamide beads to obtain the solution rich in interleukin-1 receptor antagonist. Methods for treating a site of inflammation in a patient include administering to the site of inflammation the solution rich in interleukin-1 receptor antagonist.Type: GrantFiled: August 27, 2009Date of Patent: June 17, 2014Assignee: Biomet Biologics, LLCInventors: Joel C. Higgins, Jennifer E. Woodell-May, Jacy Hoeppner
-
Patent number: 8741281Abstract: The specification discloses compositions and methods for treating a soft tissue defect of an individual.Type: GrantFiled: February 16, 2012Date of Patent: June 3, 2014Assignee: Allergan, Inc.Inventors: Dennis E. Van Epps, Guang-Liang Jiang, Adam L. Collette, Rebecca L. Horan, Jingsong Chen, Gregory H. Altman, Wha Bin Im
-
Publication number: 20140140950Abstract: Business methods, processes and systems for collection, storage and distribution of a biological sample material for producing a cosmetic formulation product.Type: ApplicationFiled: March 27, 2012Publication date: May 22, 2014Inventors: John S. Arnone, Ensley Burt
-
Publication number: 20140134264Abstract: The invention relates to the use of microvesicles (MVs) derived from stem cells for preparing a medicament for the endo/epithelial regeneration of damaged tissues or organs and/or for inhibiting the apoptosis induced by cytostatic agents. The stem cell from which the microvesicles are obtained is preferably selected from the group consisting of endothelial progenitor cells (EPCs), mesenchimal stem cells (MSCs), renal progenitors CD133+, adult human liver stem cells (HLSC) and any combination thereof. The microvesicles may be used in both in vitro and in vivo applications, such as for example the regeneration of damaged tissues or organs and the treatment of renal injury and hepatic injury, particularly acute renal failure (ARF) and acute hepatic failure (AHF).Type: ApplicationFiled: December 2, 2013Publication date: May 15, 2014Applicant: Fresenius Medical Care Deutschland GmbHInventors: Vincenzo CANTALUPPI, Maria Deregibus, Giovanni Camussi
-
Publication number: 20140112890Abstract: The invention features the production of an amine-reactive proteoglycan, specifically chondroitin sulfate or hyaluronic acid. This material can be provided in powder (solid) or liquid form and combined with blood derivatives including serum, platelets, platelet rich plasma, bone marrow, or with other tissue products to form hydrogels. The properties (physical and biological) are different for each of these hydrogels and can be further manipulated by controlling the conditions under which the hydrogels are formed. Such properties include the biodegradability of the hydrogel, the compressibility, the adhesive strength, the presence of pharmaceutical agents or therapeutic cells, and resiliency.Type: ApplicationFiled: April 2, 2012Publication date: April 24, 2014Applicant: The John Hopkins UniversityInventors: Jennifer H. Elisseeff, Iossif Strehin
-
Patent number: 8697057Abstract: The specification discloses compositions and methods for treating a soft tissue defect of an individual.Type: GrantFiled: February 16, 2012Date of Patent: April 15, 2014Assignee: Allergan, Inc.Inventors: Dennis E. Van Epps, Guang-Liang Jiang, Wha Bin Im
-
Patent number: 8697059Abstract: The present specification discloses compositions and methods for use in breast augmentation procedures. The compositions include adipose tissue and compounds that upregulate both FGF-2 and VEGF, promote new blood vessel formation thereby reducing tissue volume loss and increasing survival rate of the adipose tissue when the composition is introduced into breast tissue.Type: GrantFiled: May 3, 2013Date of Patent: April 15, 2014Assignee: Allergan, Inc.Inventors: Dennis Van Epps, Guang-Liang Jiang, Wha Bin Im
-
Patent number: 8697056Abstract: The present specification discloses compositions and methods of transplanting tissue useful for treating a soft tissue condition of an individual.Type: GrantFiled: July 29, 2011Date of Patent: April 15, 2014Assignee: Allergan, Inc.Inventors: Dennis E. Van Epps, Guang-Liang Jiang, Wha Bin Im
-
Publication number: 20140087001Abstract: The present invention relates to methods for the preparation of compositions comprising adipose tissue-derived secretions, for example those derived from bovine adipose tissue, and the use of such compositions in the preparation of a pharmaceutical composition for topical use. The invention also relates to the use of adipose tissue-derived secretions and pharmaceutical compositions thereof for the topical treatment of a non-inflammatory condition, for example the treatment of a skin condition, and for the stimulation of hair growth in a subject by topical application. The invention also relates to the use of adipose tissue-derived secretions and pharmaceutical compositions thereof for the topical treatment of acne.Type: ApplicationFiled: March 15, 2012Publication date: March 27, 2014Inventors: Graham Vesey, Rebecca Anne Webster
-
Publication number: 20140088339Abstract: Methods for treating a cardiovascular disorder comprising concomitant administration of one or more extracellular matrix (ECM) based compositions directly to damaged or diseased cardiovascular tissue associated with the cardiovascular disorder, and provision of ventricular assistance. In a preferred embodiment, the ECM based compositions include an ECM material derived from a mammalian source.Type: ApplicationFiled: March 1, 2013Publication date: March 27, 2014Applicant: Francis Law GroupInventor: Robert Matheny
-
Publication number: 20140079802Abstract: Methods to treat nervous system conditions. In at least one embodiment of a method of treating a mammalian patient having a neuronal injury or insult of the present disclosure, the method comprises the step of administering a therapeutically-effective dose of a stem cell conditioned medium to a mammalian patient, the stem cell conditioned medium comprising a cell culture supernatant containing at least one factor capable of exerting effective neuroprotection to treat a mammalian neural injury or insult.Type: ApplicationFiled: September 5, 2013Publication date: March 20, 2014Inventors: Keith Leonard March, Brian H. Johnstone, Yansheng Du
-
Publication number: 20140072650Abstract: Disclosed is an antihypertensive composition containing as an active ingredient a gelatin extract made from the skins of a skate ray and a peptide isolated from the extract. The present invention is directed to a pharmaceutical composition for a hypertension prevention and therapy containing as an active ingredient a hydrolysate of a gelatin extract isolated from the skins of a skate ray, a method for preparing a hydrolysate of a gelatin extract made from the skins of a skate ray, and the use of a new peptide having an antihypertensive activity isolated and purified from the hydrolysate.Type: ApplicationFiled: October 31, 2012Publication date: March 13, 2014Applicant: Pukyong National University Industry-University Cooperation FoundationInventors: Se-Kwon KIM, Bo-Mi RYU
-
Publication number: 20140065238Abstract: The invention provides methodologies and apparatus for producing acellular soft-tissue implants, both in small quantities and in commercializable quantities. Such soft-tissue implants include vascular graft substitutes. An acellular graft is produced by subjecting the tissue sample to an induced pressure mediated flow of an extracting solution, followed by inducing a pressure mediated flow of a treating solution, then washing the treated tissue to produce the acellular graft. The acellular grafts produced are uniform and nonimmunogenic. The inventive method allows for the production of multiple decellularized soft tissue implants, where processing time is significantly less than prior art processes and the number of implants produced per day is increased over prior art processes. In clinical use, the decellularized grafts produced exhibit significantly improved in long-tem durability and function.Type: ApplicationFiled: October 31, 2013Publication date: March 6, 2014Applicant: LifeNet HealthInventors: Lloyd Wolfinbarger, JR., Peny Lange, Alyce Linthurst-Jones, Eric Moore, Barry Naif
-
Publication number: 20140023622Abstract: Methods of developing and using cell lines, such as stem cell lines, for therapeutic or cosmetic use. In one embodiment the cell lines are used to treat a wide range of degenerative and metabolic disorders including, but not limited to, obesity, diabetes, hypertension, and cardiac deficiency. Also described are methods of using such cell lines to screen for compounds that play a role in regulating a variety of processes.Type: ApplicationFiled: July 1, 2013Publication date: January 23, 2014Inventors: Francisco Javier Silva, Mark Weinreb, Amit N. Patel, David A. Bull
-
Publication number: 20140017311Abstract: A dried product of an extract from inflammatory rabbit skin inoculated with vaccinia virus having an inhibitory activity for the production of a kallikrein-like substance is produced by admixing the extract with a saccharide, sugar alcohol or ascorbic acid before reaching dryness, and then drying the admixture to a solid form such as granules. The dried product may be employed to produce a solid preparation for oral administration, such as tablets, having an inhibitory activity for the production of a kallikrein-like substance.Type: ApplicationFiled: September 19, 2013Publication date: January 16, 2014Applicant: NIPPON ZOKI PHARMACEUTICAL CO., LTD.Inventors: Masaharu KUROHASHI, Yoji SHIBAYAMA
-
Publication number: 20140004206Abstract: Compositions and methods useful in the reduction of localized fat deposits and tightening of loose skin in subjects in need thereof using pharmacologically active detergents are disclosed. The pharmacologically active detergent compositions can additionally include anti-inflammatory agents, analgesics, dispersion or anti-dispersion agents and pharmaceutically acceptable excipients. The pharmacologically active detergent compositions are useful for treating localized accumulations of fat including, for example, lower eyelid fat herniation, lipodystrophy and fat deposits associated with cellulite and do not require surgical procedures such as liposuction.Type: ApplicationFiled: June 13, 2013Publication date: January 2, 2014Applicants: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Michael S. Kolodney, Adam M. Rotunda
-
Patent number: 8613957Abstract: A scaffold material for wound care and/or other tissue healing applications and methods for making the same is described. The scaffold material is constituted of a decellularized extracellular matrix from fish skin. The scaffold material may also include lipids from the lipid layer of the fish skin. Methods for making and using the scaffold material are also described.Type: GrantFiled: October 6, 2010Date of Patent: December 24, 2013Assignee: Kerecis EHFInventors: Gudmundur Fertram Sigurjonsson, Dora Hlin Gisladottir, Gudmundur Gudmundsson
-
Patent number: 8591930Abstract: Described are tissue graft constructs that include submucosa and other extracellular matrix materials that incorporate a number of exogenous proteins. Further described are methods for making tissue graft constructs that include stripping endogenous heparin binding proteins from a porcine graft material and thereafter binding one or more human growth factors to the native heparin molecules that are retained within the graft material. Such graft materials may be used in methods for the treatment of wounds in patients.Type: GrantFiled: April 28, 2008Date of Patent: November 26, 2013Assignee: Cook Biotech IncorporatedInventors: Michael C. Hiles, Andrew Brightman, Abram D. Janis
-
Publication number: 20130302436Abstract: The present application is directed to the field of implants comprising soft tissue for use in implantation in humans. The soft tissue implants of the present application are preferably obtained from xenograft sources. The present application provides a chemical process that sterilizes, removes antigens from and/or strengthens xenograft implants. The present techniques yield soft tissue implants having superior structural, mechanical, and/or biochemical integrity. The present application is also directed to processes for treating xenograft implants comprising soft tissues such as dermis, and to implants produced by such processes.Type: ApplicationFiled: March 14, 2013Publication date: November 14, 2013Inventors: Arnd WILHELMI, Silke Schreiner
-
Publication number: 20130287741Abstract: Flowable matrix compositions and methods of their use and manufacture are provided. Exemplary compositions may include a flowable, syringeable, putty-like form of acellular human dermal matrix. In some cases, compositions may include a moldable acellular collagen extracellular matrix. In use, the matrix compositions can be used to fill or treat skin voids, channel wounds, and other soft tissue deficiencies.Type: ApplicationFiled: December 12, 2012Publication date: October 31, 2013Inventor: AlloSource
-
Patent number: 8568789Abstract: A dried product of an extract from inflammatory rabbit skin inoculated with vaccinia virus having an inhibitory activity for the production of a kallikrein-like substance is produced by admixing the extract with a saccharide, sugar alcohol or ascorbic acid before reaching dryness, and then drying the admixture to a solid form such as granules. The dried product may be employed to produce a solid preparation for oral administration, such as tablets, having an inhibitory activity for the production of a kallikrein-like substance.Type: GrantFiled: February 2, 2012Date of Patent: October 29, 2013Assignee: Nippon Zoki Pharmaceutical Co., Ltd.Inventors: Masaharu Kurohashi, Yoji Shibayama
-
Patent number: 8557581Abstract: The present invention is a process for preparing soft tissue such as tendons, ligaments, cartilage, fascia, dermis, human valves and human veins for implant in a human and removes cellular components and forms an decellular matrix having as major components collagens and elastins while sterilizing the tissue. The process comprises the following steps: (1) isolating from a suitable donor a desired soft tissue sample of the biological material; (2) processing and decellularizing the soft tissue including inspection for visual defects, trimming and soaking the tissue in a detergent depending on whether the tissue is fascia or dermis and rinsing same with sterile water; (3) sterilizing the soft tissue in a vacuum and soaking the tissue in an antibiotic composition or peracetic acid depending on whether the soft tissue is fascia or dermis and rinsing same; (4) processing the tissue by cutting the tissue to size and perforating the tissue; and (5) dipping the tissue in 70% ethanol and packaging the tissue.Type: GrantFiled: May 3, 2010Date of Patent: October 15, 2013Assignee: Musculoskeletal Transplant FoundationInventors: Manh-Dan Ngo, Katherine Gomes Truncale, Jeffrey S. Cartmell, Carina Syring, Rudiger Von Versen
-
Publication number: 20130251670Abstract: Described are methods of treating macular edema, as well as other complications of ocular inflammation, through the administration of various stem cell populations and conditioned media thereof. In one embodiment a patient suffering from macular edema is administered an intramuscular dose of media conditioned by placental mesenchymal stem cells at a sufficient concentration and frequency to elicit a reduction in ocular inflammation. Other embodiments of the invention teach intra-ocular, intravenous, sublingual, and oral means of delivery conditioned media from various stem cell populations that has been optimized for anti-inflammatory, regenerative, and immune modulatory properties.Type: ApplicationFiled: September 13, 2012Publication date: September 26, 2013Applicant: Aidan Products, IncInventors: Neil H. Riordan, Jorge Paz Rodriguez
-
Patent number: 8541032Abstract: Disclosed are tissue graft compositions made of materials having different densities, methods of making, and methods of treatment for restoring tissues in a patient.Type: GrantFiled: October 11, 2012Date of Patent: September 24, 2013Assignee: ACell, Inc.Inventor: Miles Grody
-
Patent number: 8535719Abstract: Provided herein is a biohybrid elastomeric scaffold comprising a synthetic polymeric component and a biological polymeric component. The scaffold can be fabricated to have many different forms, non-limiting examples of which include a non-woven fibrous mesh or in a porous composite. Methods of use of the biohybrid elastomeric scaffolds in wound healing and tissue regeneration are also provided.Type: GrantFiled: July 6, 2007Date of Patent: September 17, 2013Assignee: University of Pittsburgh - Of the Commonwealth System of Higher EducationInventors: Stephen F. Badylak, Donald O. Freytes, Thomas W. Gilbert, Jianjun Guan, John Stankus, William R. Wagner